{"id":99888,"date":"2023-05-12T12:48:56","date_gmt":"2023-05-12T12:48:56","guid":{"rendered":"http:\/\/lebanonnewsgazette.com\/?guid=e131aa3cdb90155f6ca1867c61cc1a1d"},"modified":"2023-05-12T12:48:56","modified_gmt":"2023-05-12T12:48:56","slug":"uae-biotech-insilico-medicine-offers-disease-modeling-and-target-identification-course-using-ai","status":"publish","type":"post","link":"https:\/\/lebanonnewsgazette.com\/uae-biotech-insilico-medicine-offers-disease-modeling-and-target-identification-course-using-ai\/","title":{"rendered":"UAE Biotech Insilico Medicine Offers Disease Modeling and Target Identification Course Using AI"},"content":{"rendered":"
Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) — Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced that it is releasing a course on Disease Modeling and Target Identification<\/a>, available for free. Through seven lectures, the course guides participants through the latest insights in disease modeling and target discovery \u2013 critical areas in biomedical research that involve using computational and experimental approaches to gain insights into the causes of diseases and identify potential targets for drug development.<\/p>\n The course uses case studies to illustrate the practical application of the concepts covered. In particular, learners will have the opportunity to explore a demo version of PandaOmics, Insilico Medicine\u2019s generative AI tool for target discovery, which is being developed by a team of scientists at the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Center in Abu Dhabi, the region\u2019s largest AI-powered biotechnology research center.<\/p>\n PandaOmics is used by numerous pharmaceutical companies and to develop the 31 pharmaceutical assets advancing in Insilico\u2019s own pipeline \u2013 including two drugs for idiopathic pulmonary fibrosis and COVID-19 currently in clinical trials.<\/p>\n After completing the course, participants will gain:\u00a0 .<\/p>\n The course is geared toward anyone interested in drug discovery, biomedical research, and healthcare innovation, including researchers, scientists, pharmaceutical professionals and students pursuing a degree in molecular biology, chemistry, or related fields who want to see how fundamental science can be applied to the development of novel therapeutics.<\/p>\n \u201cThis course aligns with our larger mission to accelerate the discovery and development of new therapeutics by making technological breakthroughs accessible to all scientists, including students, who might be interested in pursuing AI drug discovery,\u201d says Insilico Medicine founder and CEO Alex Zhavoronkov, PhD, who is one of the course instructors.<\/p>\n Insilico has supported young researchers in using its platform before. Three high school researchers used PandaOmics to uncover new targets for glioblastoma and aging, the results of which were recently published in the journal Aging<\/a>. And Insilico has been a supporter of the Youth Longevity Association and annually sponsors young scientists to attend the Aging Research and Drug Discovery conference<\/a> in Copenhagen, a signature event that Zhavoronkov cofounded.<\/p>\n About Insilico Medicine<\/strong><\/p>\n Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. In early 2023, the Company opened the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Centre in Abu Dhabi, the region\u2019s largest AI-powered biotechnology research center. The R&D hub brings together global talent in artificial intelligence and software development to expand the capabilities of Insilico\u2019s end-to-end AI-driven drug discovery platform, Pharma.AI, explore aging research and sustainable chemistry, and support the digital transformation of healthcare in the region.<\/p>\n For more information, visit www.insilico.com<\/a><\/p>\n Attachments<\/strong><\/p>\n GlobeNewswire Distribution ID 8838367<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":" Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) \u2014 Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced that it is releasing a course on Disease Modeling and Target Identification, available for free. Through seven lectures, the course guides participants through the latest insights in disease modeling and target discovery \u2013 critical areas in [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2584,17,53,343],"tags":[],"yoast_head":"\n\n
\n
Brita Belli\r\nInsilico Medicine\r\n475-225-0843\r\nbrita@insilico.com<\/a>\r\n<\/pre>\n